| DC Field | Value | Language |
|---|
| dc.contributor.author | Korokina, L. V. | - |
| dc.contributor.author | Zhernakova, N. I. | - |
| dc.contributor.author | Korokin, M. V. | - |
| dc.contributor.author | Pokopejko, O. N. | - |
| dc.date.accessioned | 2022-04-27T14:49:28Z | - |
| dc.date.available | 2022-04-27T14:49:28Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.citation | Principles of pharmacological correction of pulmonary arterial hypertension / L.V. Korokina [et al.] // Research result: pharmacology and clinical pharmacology. - 2018. - Vol. 4, № 2.- P. 59-76. - Doi: 10.3897/rrpharmacology.4.27732. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46413 | - |
| dc.description.abstract | Prostanoids are a promising group of drugs for the treatment of pulmonary arterial hypertension (PAH), since they possess not only vasodilating, but also antiplatelet and antiproliferative actions. Therefore, it seems logical to use prostacyclin and its analogs to treat patients with various forms of PAH | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | classification | ru |
| dc.subject | pulmonary hypertension | ru |
| dc.subject | pathogenetic therapy | ru |
| dc.subject | primary therapy | ru |
| dc.subject | prostanoids | ru |
| dc.subject | pharmacological correction | ru |
| dc.title | Principles of pharmacological correction of pulmonary arterial hypertension | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 4, № 2
|
